SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. What is the class period? November 4, 2024 - October 3, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who pur ...